US2017369884A1PendingUtilityA1

MicroRNAs Sensitize Cancers to Therapy

Assignee: BAYLOR COLLEGE MEDICINEPriority: Jul 12, 2012Filed: Sep 11, 2017Published: Dec 28, 2017
Est. expiryJul 12, 2032(~5.9 yrs left)· nominal 20-yr term from priority
A61K 31/7088A61K 45/06A61K 9/0019C12N 2320/31C12N 2310/141C12N 15/1135A61P 35/00C12N 15/113C12N 2330/10C12N 2320/11A61K 33/24A61K 33/243
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention concerns methods and compositions regarding one or more microRNAs or variants thereof that are provided to an individual for a variety of medical treatments, including sensitization to cancer therapy or prevention of a cancer to become sensitized to a cancer therapy. In specific embodiments, the microRNAs include miR-520a (including at least miR-520a-3p and miR-520-5p), miR-520g, miR-520h, and functional variants thereof. In some embodiments, the cancer is ovarian cancer, and in particular embodiments, the cancer therapy is platinum-based chemotherapy.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of sensitizing uterine cancer in an individual to a cancer treatment that is platinum-based chemotherapy, comprising the step of administering to the individual an effective amount of a composition as follows:
 a RNA polynucleotide comprising SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3,   wherein upon administering the composition to the individual, the uterine cancer is thereby sensitized to the platinum-based chemotherapy treatment.   
     
     
         2 . The method of  claim 1 , wherein the composition is delivered to the individual by liposome, nanosphere, nanoparticle, nanodiamonds, impregnanted polymer, multistage nanoparticles and/or gels. 
     
     
         3 . The method of  claim 1 , wherein the composition is delivered to the individual intravenously or intraperitoneally. 
     
     
         4 . The method of  claim 1 , wherein the composition is delivered to the individual prior to the cancer treatment. 
     
     
         5 . The method of  claim 1 , wherein the composition is delivered to the individual subsequent to the cancer treatment. 
     
     
         6 . The method of  claim 1 , wherein the composition is delivered to the individual concomitantly with the cancer treatment.

Join the waitlist — get patent alerts

Track US2017369884A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.